Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect of TAK-536TCH in Healthy Japanese Men
NCT02348658Phase 1Completed
- Sponsor
- Takeda
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azilsartan + amlodipine + hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Takeda. Primary endpoints: Maximum Plasma Concentration for TAK-536, Its Metabolites (M-I and M-II) and Hydrochlorothiazide (HCTZ), Maximum Plasma Concentration for Amlodipine Besilate (AML) and 5 more. Started Jan 2015; status: completed.
02
Drugs
azilsartan + amlodipine + hydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02348658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348658.